Mitsubishi Carisma

Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 21, 2024
Entrepreneurship, Doctor of Pharmacy, Doctor of Philosophy, Engineering, Mitsubishi Carisma, AACR, Therapy, CARM, NK

PHILADELPHIA, March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.

Key Points: 
  • PHILADELPHIA, March 21, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.
  • The poster presentation will showcase preclinical data illustrating the advancements made with Carisma's proprietary Engineered Microenvironment Converters (EM-C) platform.
  • Furthermore, Michael Klichinsky, PharmD, PhD, Co-Founder, and Chief Scientific Officer at Carisma, will present "Engineering Macrophages for Cancer Immunotherapy: CARs and Beyond" during the Major Symposium session titled "Engineering Strategies Based on NK, gd T Cells and Their Receptors, and Macrophages," scheduled for Wednesday, April 10, 2024, from 10:15 AM to 11:45 AM PT.
  • Details on the poster presentation at AACR 2024 are below:

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

Retrieved on: 
Thursday, December 14, 2023
Entrepreneurship, Therapy, LNP, IND, Doctor of Pharmacy, Northwest Biotherapeutics, Patient, Myelocyte, Messenger, CARM, SITC, Doctor of Philosophy, Cancer, RNA, Pharmaceutical industry, Moderna, Mitsubishi Carisma

PHILADELPHIA, Dec. 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA). This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need. This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.

Key Points: 
  • This first lead candidate will target an antigen present on a solid tumor with significant unmet medical need.
  • This strategic collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.
  • "The delivery of this first candidate demonstrates our ability to create novel in vivo CAR therapies that can be advanced toward the clinic.
  • We look forward to completing IND-enabling studies with the lead candidate and are excited about the prospect of bringing this therapy forward for patients with advanced solid tumors together with Moderna."

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Retrieved on: 
Tuesday, November 28, 2023
Safety, Food, Entrepreneurship, Therapy, Cohort, Doctor of Pharmacy, Disease, Monocyte, Macrophage, Patient, FDA, Immunotherapy, Investigational New Drug, HER2, CARM, Doctor of Philosophy, The Society, Medical imaging, IND, Mitsubishi Carisma

PHILADELPHIA, Nov. 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the clearance of its Investigational New Drug application (IND) by the U.S. Food and Drug Administration (FDA) for CT-0525, an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Having received a Study May Proceed notification from the FDA, Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.

Key Points: 
  • Having received a Study May Proceed notification from the FDA, Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024.
  • "Clearance of the IND for CT-0525 is a significant milestone in Carisma's mission to develop innovative myeloid cell therapies for metastatic solid tumors," said Steven Kelly, President and Chief Executive Officer of Carisma.
  • "Through this Phase 1 study, we aim to advance our understanding of safety, tolerability, manufacturing feasibility and mechanism of action of CT-0525."
  • The Phase 1 study for CT-0525 is designed to assess the safety, tolerability, and the manufacturing feasibility of CT-0525.

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Retrieved on: 
Tuesday, October 31, 2023
CAR, Therapy, Society for Immunotherapy of Cancer, CARM, Doctor of Philosophy, Entrepreneurship, SITC, Immunotherapy, Doctor of Pharmacy, Messenger, Annual general meeting, LNP, PT, Society, Cancer, Patient, Myelocyte, Pharmaceutical industry, Vaccine, Mitsubishi Carisma, Moderna

PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna. The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.

Key Points: 
  • The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.
  • Accepted as a late-breaking presentation, " In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy ," showcases data that demonstrate Carisma's CAR-M therapy can be directly produced in vivo, or within the body, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP.
  • "We are pleased to share data about the successful application of our mRNA platform to advance in vivo cell therapy," said Lin Guey, PhD, Chief Scientific Officer of External Research Ventures at Moderna.
  • Details of Carisma data accepted for presentation at the SITC 38th Annual Meeting are as follows:

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023

Retrieved on: 
Thursday, August 24, 2023
Mitsubishi Carisma, Entrepreneurship, Doctor of Philosophy, Doctor of Pharmacy, Therapy, CARM, Pharmaceutical industry, Management

PHILADELPHIA, Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023.

Key Points: 
  • PHILADELPHIA, Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at two healthcare industry conferences in September 2023.
  • These conferences include:
    Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer, will give a presentation during the summit.
  • Michael Klichinsky, PharmD, PhD, Co-Founder and Chief Scientific Officer, will give a presentation during the meeting.
  • A replay of webcasts, when available, will be posted and archived at Carisma's Investor Events webpage for a limited time following the event.

Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources

Retrieved on: 
Wednesday, June 14, 2023
Human resources, Senior, General counsel, Mitsubishi Carisma, Human, Idorsia, Jazz Pharmaceuticals, Patient, Corporation, Cancer, CARM, HR, Therapy, Pharmaceutical industry, Management

PHILADELPHIA, June 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma Therapeutics" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates today. Eric Siegel has been appointed General Counsel and Corporate Secretary and Terry Shields has been named Senior Vice President of Human Resources. Prior to joining Carisma Therapeutics, Mr. Siegel was Chief Compliance Officer for Idorsia Pharmaceuticals US Inc. Ms. Shields is joining the Carisma Therapeutics team after 25 years of experience as a human resources consultant for start-up and fast-growth life science companies and four years as a consultant for Carisma Therapeutics.

Key Points: 
  • PHILADELPHIA, June 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma Therapeutics" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates today.
  • Eric Siegel has been appointed General Counsel and Corporate Secretary and Terry Shields has been named Senior Vice President of Human Resources.
  • Prior to joining Carisma Therapeutics, Mr. Siegel was Chief Compliance Officer for Idorsia Pharmaceuticals US Inc. Ms. Shields is joining the Carisma Therapeutics team after 25 years of experience as a human resources consultant for start-up and fast-growth life science companies and four years as a consultant for Carisma Therapeutics.
  • "Having had the opportunity to work with Carisma the past four years, I am confident moving into this role will be a smooth transition and I am looking forward to continuing to support the team in this new position," said Terry Shields, Senior Vice President, Human Resources at Carisma Therapeutics.

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023

Retrieved on: 
Tuesday, May 30, 2023
Mitsubishi Carisma, Macrophage, Therapy, MD, Entrepreneurship, Pharming, CARM, Pharmaceutical industry

PHILADELPHIA, May 30, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several healthcare industry conferences in June 2023.

Key Points: 
  • PHILADELPHIA, May 30, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several healthcare industry conferences in June 2023.
  • These conferences include:
    Yara Abdou, MD, will present trials in progress poster during the meeting:
    Michael Klichinsky, Pharm.D., Ph.D., Co-Founder & Chief Scientific Officer will give a presentation on Carisma's revolutionary CAR-M approach.
  • Tom Wilton, Chief Business Officer, will give a presentation titled "CAR-M: Driving Anti-Tumor Immunity with Chimeric Antigen Receptor Macrophages."
  • A replay of webcasts, when available, will be posted and archived at Carisma's Investor Events webpage for a limited time following the event.

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023

Retrieved on: 
Friday, May 5, 2023
Mitsubishi Carisma, Protein engineering, Macrophage, Entrepreneurship, Pharming, Mobile phone

Michael Klichinsky, Pharm.D., Ph.D., Co-Founder & Chief Scientific Officer will give a presentation titled "Beyond T-cells: CAR-Macs, CAR-NKs."

Key Points: 
  • Michael Klichinsky, Pharm.D., Ph.D., Co-Founder & Chief Scientific Officer will give a presentation titled "Beyond T-cells: CAR-Macs, CAR-NKs."
  • Nicholas Minutolo, Ph.D., Head of Protein Engineering, will give a presentation titled "Advances in CAR-M Cellular Immunotherapy" during the meeting.
  • Michael Klichinsky, Pharm.D., Ph.D., Co-Founder & Chief Scientific Officer, will give a presentation titled "Genetically engineering macrophages: CAR-M and Beyond."
  • A replay of webcasts, when available, will be posted and archived at Carisma's Investor Events webpage for a limited time following the event.

MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary

Retrieved on: 
Thursday, April 13, 2023
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Intellectual property, General counsel, JPMorgan Chase, University, HCI Equity Partners, Troutman Pepper, Mitsubishi Carisma, Private practice, Corporation, CARM, NEO, Medicine, MindMed, Management

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary.
  • Mark brings tremendous legal and public company life sciences expertise and will be a strong addition to our executive team.
  • We believe Mark’s experience, insights and guidance will prove invaluable as MindMed progresses to the next stage of its evolution.
  • I look forward to working closely with Mark during this transformative time for the company,” said Robert Barrow, Chief Executive Officer and Director of MindMed.

Carisma Therapeutics Closes Merger with Sesen Bio

Retrieved on: 
Tuesday, March 7, 2023
Shearman, University of Pennsylvania Health System, Symbiosis, SVB, Patient, SVB Securities, AbbVie, HealthCap, Shearman & Sterling, Growth, Sale, CARM, Therapy, Solasta: Crown of the Magister, Wellington Partners, Cancer, Merck & Co., BofA Securities, Immunotherapy, Caregiver, Wilmer Cutler Pickering Hale and Dorr, Merck, Cryptocurrency, Nursing, Management, Mitsubishi Carisma

PHILADELPHIA, March 7, 2023 /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, and Sesen Bio, Inc. ("Sesen Bio"), announced today the closing of their previously announced merger. The combined company will operate under the name Carisma Therapeutics Inc. and shares of its common stock will commence trading under the ticker symbol "CARM" on March 8, 2023 on the Nasdaq Capital Market.

Key Points: 
  • Shares of Carisma to commence trading on Nasdaq under new ticker symbol "CARM" on March 8, 2023
    Resulting cash position of approximately $140 million provides runway through 2024; expected to enable multiple clinical readouts across Carisma programs
    PHILADELPHIA, March 7, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, and Sesen Bio, Inc. ("Sesen Bio"), announced today the closing of their previously announced merger.
  • Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "I want to thank the entire Sesen Bio team for their steadfast commitment to our mission to save and improve lives.
  • Patients, caregivers and investigators around the world have been important advocates of Sesen Bio and I want to thank them for their support.
  • SVB Securities acted as the exclusive financial advisor to Sesen Bio for the transaction, and Hogan Lovells US LLP served as Sesen Bio's legal counsel.